Company profile: PCI Biotech
1.1 - Company Overview
Company description
- Provider of photochemical drug delivery technologies for cancer therapy, focusing on photochemical internalisation (PCI) to enhance intracellular delivery of therapeutic compounds for novel cancer treatments, and photochemical lysis (PCL) to improve viral vector manufacturing through light-triggered cell lysis that increases yield and reduces impurities.
Products and services
- Photochemical Internalisation (PCI): Photochemical-based platform that disrupts endosomal membranes to enhance intracellular delivery, enabling anticancer therapeutics to reach intracellular targets within cells for precise treatment
- FimaCHEM: PCI-enabled treatment paradigm enhancing chemotherapeutics for localized cancer therapy, employing photochemical internalisation to enhance chemotherapeutic delivery at the intended treatment site
- Photochemical Lysis (PCL): Process-scale, light-triggered cell lysis method for viral vector manufacturing that increases yield and reduces impurities in the production process
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to PCI Biotech
Rakuten Medical
HQ: United States
Website
- Description: Provider of investigational cancer therapies based on the proprietary Alluminox photoimmunotherapy platform, which combines a drug with targeting moieties and a light-activating device using non-thermal illumination to selectively target cancer cells; includes ASP-1929, an Alluminox-developed drug with dye-conjugated targeting moieties, approved in Japan for treating certain cancers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Rakuten Medical company profile →
Nuvectis Pharma
HQ: United States
Website
- Description: Provider of novel targeted cancer therapeutics, including NXP800, an oral small molecule activator of GCN2 in clinical trials for platinum-resistant, ARID1a-mutated ovarian cancer and cholangiocarcinoma, and NXP900, an oral small molecule inhibitor of SRC family kinases (SFK), including SRC and YES1, currently in a Phase 1 dose escalation clinical trial.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nuvectis Pharma company profile →
Argos Therapeutics
HQ: United States
Website
- Description: Provider of immunotherapy treatments for cancer, infectious and autoimmune diseases, and transplantation rejection. Conducts clinical trial programs in cancer and HIV. Product candidates include AGS-0031 for metastatic renal cell carcinoma, AGS-0041 for HIV, and CD83.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Argos Therapeutics company profile →
Forty Seven
HQ: United States
Website
- Description: Provider of clinical-stage immuno-oncology therapies targeting cancer immune evasion pathways, based on technology licensed from Stanford University. Lead program 5F9 is a monoclonal antibody against the CD47 receptor, a 'don't eat me' signal that cancer cells commandeer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Forty Seven company profile →
ArQule
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology research and development of cancer therapeutics, employing its ArQule Kinase Inhibitor Platform (AKIP) to design and develop drugs, including ARQ 197, an orally administered inhibitor of the c-Met receptor tyrosine kinase.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ArQule company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for PCI Biotech
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to PCI Biotech
2.2 - Growth funds investing in similar companies to PCI Biotech
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for PCI Biotech
4.2 - Public trading comparable groups for PCI Biotech
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →